Category and Product-level Procurement and Delivery Planning Guide – Health and non-health products

Indicative Lead Times

Version Q2 2023 – April 2023
This information will be updated periodically, with the latest made available here.

This document lays out indicative lead times for planning purposes for key health products, including COVID-19, HIV, malaria, and non-health products, for the Global Fund’s Pooled Procurement Mechanism (PPM). This information may also be useful as a reference for other procurement channels.

Whilst many countries are relaxing their Covid-19 control measures, global supply chains remain stressed with both reduced capacity and congestion. Price pressures uncertainty remains on freight costs.

This version provides updated advice including reductions in for example airfreight lead-times with more flight routes opening for many destinations. We should however not take these reductions with any complacency though.

Principal Recipients remain advised to place orders earlier than ordinarily to compensate for these freight capacity constraints.

Very importantly, for your planning, please recall and review the following guidance on the utilization of funds related to the delivery of products:

- Products to be delivered before the grant end date: Guidelines for Grant Budgeting (Section 2.1.1.)
- For C19RM funds, products need to be delivered well before end of 2025: COVID-19 Response Mechanism Guidelines (Section 1.3)

PRs should therefore utilize this guidance to determine when to place orders to enable the products to arrive on time.

And, for more complex health equipment that requires some level of site preparation and/or installation, orders should be planned to arrive and handed over well before the end of 2025. PRs also need to ensure that any site preparation is completed before delivery to the country.

The lead-time guidance below corresponds to the average times from making a procurement request through to delivery in-country and assumes that there are no financing or other challenges that may delay confirming an order.

Orders that would therefore need long times to be approved or for countries where importation approvals take long, PRs must add the necessary additional weeks to these lead times.

During delivery, PRs need to expedite approvals for shipment to minimize the barriers to be able to move products efficiently in the context of greater complexity to enable products to be delivered in-time.

This information is provided at the category and the detailed product level and is indicative based on current market knowledge to assure on-time delivery and best value procurement in terms of product and freight costs.

This lead time document is updated regularly and can be found on the Global Fund’s website.

A similar lead time guide for TB products is available on StopTB Partnership’s Global Drug Facility’s website.
<table>
<thead>
<tr>
<th>Conservative Indicative lead time planning guide</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note that there may be some variations within the category - please consult the subsequent product level detail for more specific guidance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Specialist- or limited use ARVs</td>
<td>Late/emergency order</td>
<td>Oct-22</td>
<td>Nov-22</td>
</tr>
<tr>
<td>- CD4 / chemistry / haematology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product availability is dependent on manufacturer production schedule at time of order confirmation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Malaria</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General Laboratory equipment, consumables &amp; supplies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-health</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- For non-health products lead time significantly varies, for more details please refer to specific product lead times below.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COVID-19

*Procurement and delivery lead-time* corresponds to the time from making a procurement request through to delivery in-country and assumes that there are no financing or other challenges that may delay confirming an order. **Countries where importation approvals are complex or where the greenlight to ship is long should add the necessary additional weeks to these lead times.** This information is provided at the category and the detailed product level and is indicative based on current market knowledge to assure on-time delivery and best value procurement in terms of product and freight costs. The Administrative lead time represents the typical time for most countries required from submitting a requisition to issuance of an approved purchase order.

<table>
<thead>
<tr>
<th>Table 1: Diagnosis, Testing and Surveillance</th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - RAPID DIAGNOSTIC TESTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SARS-CoV-2 Rapid Antigen Diagnostic Test Kit</td>
<td>30 days</td>
<td>15-30 days</td>
<td>90 – 105 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - RAPID DIAGNOSTIC TESTS: Antigen-RDT Self-Test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SARS-CoV-2 Rapid Antigen Diagnostic Self-Test Kit*</td>
<td>30 days</td>
<td>15-30 days</td>
<td>90 – 105 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - AUTOMATED PCR TESTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xpert® Xpress SARS-CoV-2, 10T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Abbott RealTime SARS-CoV-2 RT-PCR Kit, 96T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>Aptima SARS-CoV-2 assay, 250T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Cobas SARS-CoV-2 RT-PCR Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Alinity m SARS-CoV-2 AMP Kit, 96T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>BD SARS-CoV-2 Reagents, 24T/Kit</td>
<td>30 days</td>
<td>45 days</td>
<td>120 days</td>
</tr>
<tr>
<td>Biofire Respiratory Panel 2.1 (RP2.1), 30T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - MANUAL PCR TESTS: Amplification kits</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alplex, 2019-nCoV Assay Kit, 100T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Diagnostic Kit for SARS-CoV-2 Nucleic Acid (Real-time PCR), 48T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV, 50T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>STANDARD M nCoV Real-Time Detection kit, 96T/Kit</td>
<td>30 days</td>
<td>45 days</td>
<td>120 days</td>
</tr>
<tr>
<td>Novel Coronavirus (2019-nCoV) Real Time Multiplex RT PCR Kit, 25T/Kit</td>
<td>30 days</td>
<td>7 days</td>
<td>82 days</td>
</tr>
<tr>
<td>TaqPath COVID-19 CE-IVD RT-PCR Kit, 1000T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Detection Kit Novel Coronavirus (2019-nCoV) RNA, (PCR- Fluorescence Probing), 96T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Wantai SARS-CoV-2 RT-PCR Kit, 48T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Smart Detect™ SARS-CoV-2 rRT-PCR Kit, 48T/Kit</td>
<td>30 days</td>
<td>45 days</td>
<td>120 days</td>
</tr>
<tr>
<td>Table 1: Diagnosis, Testing and Surveillance</td>
<td>Administrative lead time</td>
<td>Manufacturing lead time</td>
<td>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>--------------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total lead time by Air (+45 days)</td>
</tr>
<tr>
<td>COVID-19 Coronavirus Real Time PCR Kit, 50T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>GeneFinder™ COVID-19 Plus RealAmp Kit, 100T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>COVID-19 genesig® Real-Time PCR assay, 96T/Kit</td>
<td>30 days</td>
<td>7 days</td>
<td>82 days</td>
</tr>
<tr>
<td>Alplex™ 2019-nCoV Assay kit, 124T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>COVID-19 RT-PCR PNA Kit, 100T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing), 48T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>GB SARS-CoV-2 Real-Time RT PCR, 100T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - NUCLEIC ACID EXTRACTION KITS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleic Acid Extraction kit, 48T/Kit</td>
<td>30 days</td>
<td>70 days</td>
<td>145 days</td>
</tr>
<tr>
<td>MagMAX™ Viral/Pathogen II (MVP II) Nucleic Acid Isolation Kit, 2000T/Kit</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Beijing Wantai Nucleic Acid Extraction Kit, 48T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>QIamp Viral RNA Mini Kit, 250T/Kit</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>STARMag 96x4 kits</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Multi-type Sample DNA/RNA Extraction-Purification, Kit of 48 Tests</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Nucleic Acid Extraction kit, 96T/Kit</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>MagNA Pure kits</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - SAMPLE COLLECTION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sampler w/VTM, swab, kit of 100</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>COVID-19, Xpert Xpress Nasopharyngeal Sample Collection, Kit of 100</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Triple Packaging</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td>COVID-19 Diagnostic Reagents and Consumables - OTHER CONSUMABLES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BGI COVID-19 PCR Consumables, Kit of 3000 Tests</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>BD MAX PCR Cartridges, 576 per box</td>
<td>30 days</td>
<td>45 days</td>
<td>120 days</td>
</tr>
<tr>
<td>Plates (Deep Well / Well Optical / Microplate)</td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td>Pipette Tips</td>
<td>30 days</td>
<td>70 days</td>
<td>145 days</td>
</tr>
<tr>
<td>COVID-19 Molecular Test Equipment - AUTOMATED NUCLEIC ACID EXTRACTORS (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NucliSENS® easyMAG® System</td>
<td>30 days</td>
<td>45 days</td>
<td>120 days</td>
</tr>
<tr>
<td>KingFisher™ Flex Purification System</td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td>QIAsymphony® SP</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Roche MagNA Pure</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td>Automated Nucleic Acid Extractor w/software v2.4.1</td>
<td>30 days</td>
<td>70 days</td>
<td>145 days</td>
</tr>
<tr>
<td>COVID-19 Molecular Test Equipment - THERMOCYCLERS, INCLUDING RT-PCR ANALYZERS (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Applied Biosystems™ 7500</td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td>Cobas Analyzer</td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
</tr>
<tr>
<td>Table 1: Diagnosis, Testing and Surveillance</td>
<td>Administrative lead time</td>
<td>Manufacturing lead time</td>
<td>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>--------------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td><strong>Total lead time by Air (+45 days)</strong></td>
<td><strong>Total lead time by Ocean (+75 days)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CFX96 Detection system / Optical Reaction module</strong></td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td><strong>Bio-Rad, C1000 Touch, PCR Equipment / Thermal Cycler</strong></td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td><strong>Rotor-Gene Q MDx 5plex HRM Platform</strong></td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td><strong>Applied Biosystems QuantStudio (Research Use Only)</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>Roche, LightCycler II 480, PCR Equipment</strong></td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td><strong>SLAN-96P PCR system</strong></td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td><strong>BD MAX™ System</strong></td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>GeneXpert Desktop, Laptop and satellite multi-site system</strong></td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td><strong>COVID-19 Sequencing Analyzers</strong> (delivery lead time may vary in some countries depending on the regulatory and instrument compliance requirements)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Illumina iSeq 100</strong></td>
<td>60 days</td>
<td>60 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>Illumina MiniSeq</strong></td>
<td>60 days</td>
<td>60 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>Illumina MiSeq</strong></td>
<td>60 days</td>
<td>70 days</td>
<td>175 days</td>
</tr>
<tr>
<td><strong>Illumina NextSeq 550, Nextseq 1000, NextSeq 2000</strong></td>
<td>60 days</td>
<td>60 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>NovaSeq 6000</strong></td>
<td>60 days</td>
<td>125 days</td>
<td>230 days</td>
</tr>
<tr>
<td><strong>COVID-19 Molecular Test Equipment - OTHERS</strong> (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LumiraDx™ Platform</strong></td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td><strong>BD Veritor™ Plus Analyzer</strong></td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td><strong>LumiraDx SARS-CoV-2 Antigen Quality Control, Kit of 24 Tests</strong></td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td><strong>Magnetic stand: Manual extraction</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>Tabletop PCR workstation with UV light</strong></td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>UV cross linker / transilluminator</strong></td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
</tr>
<tr>
<td><strong>COVID-19 Molecular Test Equipment - OTHER CONSUMABLES - MOLECULAR TEST EQUIPMENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MagNA Pure equipment</strong></td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td><strong>MicroAmp equipment</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>TaqMan™ RNase P Instrument Verification Plate for 7300/7500 Systems, 96-well</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>96-Well TaqMan instrument Verification Plate</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>384-Well TaqMan™ RNase P Instrument Verification Plate</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>7500 Real Time PCR Systems Spectral Calibration Kit I</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>7500 Fast Real-Time PCR Systems Spectral Calibration Kit I</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>7500 Fast Real-Time PCR Systems Spectral Calibration Kit II</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>7500 Fast Real-Time PCR Systems Spectral Calibration Kit III</strong></td>
<td>30 days</td>
<td>35 days</td>
<td>110 days</td>
</tr>
<tr>
<td><strong>KingFisher 96 consumables</strong></td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
<tr>
<td><strong>Hard-Shell 96-Well PCR Plates, Low ProSlite, Thin wall, skirted, pack of 50 pieces</strong></td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
</tbody>
</table>
### Table 1: Diagnosis, Testing and Surveillance

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microseal 'B' PCR Plate Sealing Film, adhesive, optical, pack of 100 pieces</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td>0.2 ml 8-Tube PCR Strips without Caps, low profile, pack of 120 pieces</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
</tr>
<tr>
<td>Cobas kits and Consumables</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
</tr>
</tbody>
</table>

*Substantive quantities of these products available from inventory for immediate delivery if requisition approval and importation clearances can be processed quickly.

### Table 2: Infection, Prevention and Control

<table>
<thead>
<tr>
<th>Core Personal Protective Equipment (PPE) (Substantive quantities of these products available from inventory for immediate delivery if requisition approval and importation clearances can be processed quickly)</th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core PPE – Core (Gloves, Apron, Faceshield, Goggles, Gowns, Scrubs)*</td>
<td>30 days</td>
<td>7-30 days</td>
<td>82 – 105 days</td>
</tr>
<tr>
<td>Masks / Respirators*</td>
<td>30 days</td>
<td>15 days</td>
<td>90 days</td>
</tr>
<tr>
<td>Non-Core PPE</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
</tr>
<tr>
<td>PPE – Others (Coverall, Boots, Bootcover, Surgical cap, heavy-duty gloves and Apron)</td>
<td>30 days</td>
<td>30 days</td>
<td>135 days</td>
</tr>
</tbody>
</table>

*Substantive quantities of these products available from inventory for immediate delivery if requisition approval and importation clearances can be processed quickly.
### Table 3: Case Management, Clinical Operations and Therapeutics: Medical Oxygen

<table>
<thead>
<tr>
<th></th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
<th>Total lead time by Air (+45 days)</th>
<th>Total lead time by Ocean (+75 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical oxygen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Equipment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxygen analyser / Pulse oximeter</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
<td>135 days</td>
<td></td>
</tr>
<tr>
<td>Ventilation (HFNC/ BiPAP) / Concentrator / Voltage Stabilizer</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
<td>165 days</td>
<td></td>
</tr>
<tr>
<td>Medical ventilation / Patient monitoring</td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
<td>195 days</td>
<td></td>
</tr>
<tr>
<td><strong>Medical Oxygen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Pressure Swing Absorption (PSA) Oxygen Plants</td>
<td>70-110 days**</td>
<td>60-70 days***</td>
<td>N/A</td>
<td>205 – 255 days</td>
<td></td>
</tr>
</tbody>
</table>

* In general, for existing Oxygen product orders procured by UNICEF through wambo.org the lead time indications are based on FCA port of origin, these are not manufacturer lead times / CIP delivery

** Leadtime to develop plant specifications, submit requisition and approve through workflow. Global Fund Technical Assistance support is available

*** This is a combination of manufacturing lead time and installation/commissioning of the plant equipment

### Table 4: Case Management, Clinical Operations and Therapeutics: Health Equipment

<table>
<thead>
<tr>
<th></th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
<th>Total lead time by Air (+45 days)</th>
<th>Total lead time by Ocean (+75 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>X-rays</strong> (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X-Ray Unit - Ultra portable only</td>
<td>30 days</td>
<td>120 days</td>
<td>195 days</td>
<td>225 days</td>
<td></td>
</tr>
<tr>
<td>X-ray Unit - Ultra portable with options</td>
<td>30 days</td>
<td>140 days</td>
<td>215 days</td>
<td>245 days</td>
<td></td>
</tr>
<tr>
<td>X-Ray lab and clinic</td>
<td>30 days</td>
<td>120 days</td>
<td>195 days</td>
<td>225 days</td>
<td></td>
</tr>
<tr>
<td><strong>Other Health Equipment</strong> (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic drop counter for IV fluids</td>
<td>30 days</td>
<td>40 days</td>
<td>115 days</td>
<td>145 days</td>
<td></td>
</tr>
<tr>
<td>Blood gas analyzer / Electrocardiogram</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
<td>165 days</td>
<td></td>
</tr>
<tr>
<td>Ultrasound</td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
<td>195 days</td>
<td></td>
</tr>
<tr>
<td>Infusion pump</td>
<td>30 days</td>
<td>120 days</td>
<td>195 days</td>
<td>225 days</td>
<td></td>
</tr>
</tbody>
</table>
### Table 5: Pharmaceuticals

<table>
<thead>
<tr>
<th></th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time</th>
<th>Total lead time by Air (+45 days)</th>
<th>Total lead time by Ocean (+75 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dexamethasone</strong></td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Enoxaparin</strong></td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heparin</strong></td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nirmatrelvir + Ritonavir (Co-packed)</strong></td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Molnupiravir</strong></td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| *Indicative information which is subject to the Global Fund and manufacturer finalizing their agreement*

### Table 6: Health Product and Waste Management Systems

<table>
<thead>
<tr>
<th></th>
<th>Administrative lead time</th>
<th>Manufacturing lead time</th>
<th>Total lead time</th>
<th>Total lead time by Air (+45 days)</th>
<th>Total lead time by Ocean (+75 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Waste Management</strong> (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety Box 5L</td>
<td>30 days</td>
<td>30 days</td>
<td>105 days</td>
<td>135 days</td>
<td></td>
</tr>
<tr>
<td>Waste management consumables / Autoclave 40L</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
<td>165 days</td>
<td></td>
</tr>
<tr>
<td>Biohazard bags (15L; 100L)</td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
<td>195 days</td>
<td></td>
</tr>
<tr>
<td>Microwave with integrated shredder</td>
<td>30 days</td>
<td>70 – 130 days</td>
<td>145 – 205 days</td>
<td>175 – 235 days</td>
<td></td>
</tr>
<tr>
<td>Incinerators (30, 50, 100, 225, 360kg/h)</td>
<td>30 days</td>
<td>120 days</td>
<td>195 days</td>
<td>225 days</td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory Equipment</strong> (Complex equipment requires the designated site to be ready for handover at least three months before the end of 2023 in order to comply with the Global Fund budgeting guidelines)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vortex Mixer / Centrifuge</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
<td>165 days</td>
<td></td>
</tr>
<tr>
<td>Autoclave for laboratory</td>
<td>30 days</td>
<td>70 days</td>
<td>145 days</td>
<td>175 days</td>
<td></td>
</tr>
<tr>
<td>Other equipment (Biosafety Cabinet, Centrifuge, Incubator, Freezer, Thermoblock)</td>
<td>30 days</td>
<td>90 days</td>
<td>165 days</td>
<td>195 days</td>
<td></td>
</tr>
<tr>
<td><strong>Cold Chain Consumables</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cold box</td>
<td>30 days</td>
<td>20 days</td>
<td>95 days</td>
<td>125 days</td>
<td></td>
</tr>
<tr>
<td>Data logger (single use and reusable)</td>
<td>30 days</td>
<td>60 days</td>
<td>135 days</td>
<td>165 days</td>
<td></td>
</tr>
</tbody>
</table>
### HIV

**Total lead time** for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *

<table>
<thead>
<tr>
<th>ARVs</th>
<th>180 days</th>
<th>210 days</th>
<th>240 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO Recommended Optimal (first and second line ARVs routinely available with no carton)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir/Lamivudine 120/60mg tablet dispersible 30*</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir/Lamivudine 600/300mg tablet 30</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Atazanavir/Ritonavir 300/100mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir/Dolutegravir/Lamivudine 600/50/300mg tablet 30</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dolutegravir 50mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolutegravir/Lamivudine/Tenofovir 50/300/300mg tablet 30/90/180</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolutegravir 10mg</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz 200mg tablet double scored 90</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz/Lamivudine/Tenofovir 400/300mg/300mg tablet 30/90/180</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine/Tenofovir 200/300mg tablet, container of 30 tablets</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine/Tenofovir 75/75mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine/Tenofovir 300/300mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine/Zidovudine 30/60mg tablet dispersible 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine/Zidovudine 150/300mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/Ritonavir 100/25mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/Ritonavir 200/50mg tablet 120</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/Ritonavir 40/10mg capsule 120</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/Ritonavir 40/10mg oral granules –120 sachets</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nevirapine 10mg/ml oral suspension 100ml</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nevirapine 50mg tablet dispersible 30/60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialist or Limited–Use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir 60mg tablet dispersible 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir 300mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir 600mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/Ritonavir 400/50mg tabs 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir 400mg tab</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine 150mg</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir 25mg chewable tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir 100mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir 100mg oral granules sachet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir 400mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir 25mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir 100mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir 100mg tablet 60</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir 300mg tablet 30</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</td>
<td>180 days</td>
<td>210 days</td>
<td>240 days</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Zidovudine 50mg/5ml Oral solution 240ml</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Zidovudine 300mg tablet 60</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

**Strategic medicines used in HIV programs**

**Hepatitis B**

- Entecavir 0.5mg tablet 30
- Entecavir 0.5mg tablet 90
- Entecavir 1mg tablet 30
- Entecavir 1mg tablet 90
- Tenofovir 300mg tablet 30

**Hepatitis C**

- Daclatasvir 30mg tablet 28
- Daclatasvir 60mg tablet 28
- Sofosbuvir 400mg tablet 28
- Sofosbuvir+Daclatasvir 400+60mg tablet co–blistered 28 blister
- Sofosbuvir/ Ledipasvir 400mg/90mg tablet 28
- Sofosbuvir/Velpatasvir tablet 400mg/100mg tablet 28

**Medicines for the prevention of HIV related opportunistic infections**

- Isoniazid 100mg tablet 100
- Isoniazid 300mg tablet 30
- Isoniazid 300mg tablet 672
- Isoniazid 300mg tablet 1000
- Isoniazid/cotrimoxazole/vitamin B6 300/960/25mg tablet 30
- Rifapentine 150mg tablet 24
- Isoniazid/Rifapentine 300/300mg 36 tablet

**Medicines for Kaposi Sarcoma**

- Pegylated liposomal doxorubicin 2mg/ml 20/50mg 1 vial

**Medicines for cryptococcal disease**

- Amphotericin B liposomal 50mg for injection – 10 vials
- Flucytosine tablet 500mg tablet 100
- Flucytosine injection 10mg/ml 5 bottles 250ml

**HIV Rapid Diagnostic Test** (Non–exhaustive list – refer to Global Fund QA Policy for additional products)

- ABON™ HIV 1/2/O Tri–Line HIV Rapid Test Device 40 tests (accessories included)
- ALERE HIV COMBO SET 100 tests (accessories included)
- Beijing Wantai Rapid Test for Antibody to Human Immunodeficiency Virus (HIV) (Colloidal Gold Device) 50 tests (accessories included)
- DETERMINE HIV 1/2 SERUM/PLASMA 100 tests (accessories included)
- Diaquick HIV plus 25 tests
- Diaquick HIV plus WB 25 tests
- First Response HIV 1–2 O Card Test. Premier medical 30, 60 or 100 tests (accessories included)
### Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *

<table>
<thead>
<tr>
<th>Product</th>
<th>180 days</th>
<th>210 days</th>
<th>240 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV 1/2 Stat Pak 20 tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MULTISURE® HIV Rapid Test 20 tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>SD BIOLINE HIV 1/2 3.0 (accessories included)</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Shanghai Kehua Diagnostic Kit for HIV(1+2) Antibody (Colloidal Gold) V2 50 tests (accessories included)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toyo Anti–HIV 1/2 25 tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Uni–Gold HIV 100 tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Wondfo® One Step HIV 1/2 Whole Blood/Serum/Plasma Test 40 tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>HIV 1+2 - OraQuick HIV Rapid Antibody Kit - accessories included</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>HIV–self tests</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Condoms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female condom – 1 piece</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Male condom – pack of 144</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Lubricants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lubricant 4/4.3/5 ml – water based – 1000 sachets</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Viral Load</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbott Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load / EID + consumables</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Biocentric Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load + consumables</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Biomerieux Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load + consumables</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Cepheid Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load / EID</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Hologic Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Qiagen Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load + consumables</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Roche Instrument</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Viral Load / EID + consumables</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
## Malaria

<table>
<thead>
<tr>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
<th>210 days</th>
<th>240 days</th>
<th>270 days</th>
<th>300 days</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACTs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artemether/Lumefantrine 3/6/12/24 tablet 30 blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate/Amodiaquine 3/6 tablet 25 blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other ACTs and antimalarial medicines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate/Mefloquine 3/6 tablet</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate 60mg powder for solution for injection – 1 vial</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate 100mg suppository 2</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amodiaquine (as hydrochloride)+Sulfadoxine/Pyrimetamine 76.5mg+250/12.5mg 3+1 tablet dispersible co–blistered 50 blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amodiaquine (as hydrochloride)+Sulfadoxine/Pyrimetamine 153mg+500/25mg 3+1 tablet dispersible co–blistered 50 blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artesunate/Pyranoridine 20/60mg granule 90</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Artesunate/Pyranoridine 60/180mg tablet 9 tablet 10 blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piperaquine tetraphosphate (as the tetrahydrate;PQP)/Dihydroartemisinin (DHA) 3/6/9/12 tablet</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfadoxine/Pyrimetamine tablet/blister</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primaquine 7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine (as Phosphate) 250mg as phosphate (155mg as base)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Malaria Rapid Diagnostic Tests</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test Kit – Antigen Pf – accessories included – 25 tests</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test kit – Antigen Pf – POCT – accessories included – 25 x 1 test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test Kit – Antigen Pf / Pv – accessories included – 25 tests</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test Kit – Antigen Pf / Pv – POCT – accessories included – 25 x 1 test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test Kit – Antigen Pf/Pan – accessories included – 25 tests</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Test Kit – Antigen Pf/Pan – POCT – accessories included – 25 x 1 test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LLINs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LLIN – Pyrethroid</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LLIN – PBO</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IRS (Indoor Residual Sprays)</strong> (Non-exhaustive list – refer to Global Fund QA Policy for additional products)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder – WP) 62.5g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder – WP) 100g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder – WP) 125g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder in water soluble bag – WP–SB) 62.5g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder in water soluble bag – WP–SB) 100g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendiocarb 80% (wettable powder in water soluble bag – WP–SB) 125g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clothianidin 50% [SUMISHIELD] (water dispersible granules – WG) 150g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clothianidin &amp; Deltamethrin 56.25% [FLUDORA FUSION] (wettable powder in water soluble bag – WP–SB), 80g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery)</td>
<td>210 days</td>
<td>240 days</td>
<td>270 days</td>
<td>300 days</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Clothianidin &amp; Deltamethrin 56.25% [FLUDORA FUSION] (wettable powder in water soluble bag – WP–SB), 100g</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Deltamethrin 25% (water dispersible granules – WG) 20g</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deltamethrin 25% (water dispersible granules – WG) 25g</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Deltamethrin 5% (wettable powder – WP) 100g</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Dichlorodiphenyltrichloroethane (DDT) 75% (wettable powder – WP) 670g</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lambda-cyhalothrin 10% (capsule suspension – CS) 62.5ml</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pirimiphos–methyl [ACTELLIC] 300 g/L (capsule suspension – CS) 833ml</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Non–health

<table>
<thead>
<tr>
<th>Total lead time for planning in the context of COVID-19 impact on Supply Chain (DAP delivery) *</th>
<th>150 days</th>
<th>180 days</th>
<th>210 days</th>
<th>240 days</th>
<th>270 days</th>
<th>300 days</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Motor vehicles</strong> (Challenging market conditions (microchip shortages, force majeure events etc.) result in lead times being 13 months)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex–stock Motor vehicles</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex–factory Motor vehicles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Motorcycles</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex–stock Motorcycles</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex–factory Motorcycles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Trucks</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flat bed / Cargo / Refrigerated trucks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Buses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minibuses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Buses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Ambulances</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex–stock ambulances</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Ex–factory ambulances</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Mobile clinics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynecological clinics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Mobile laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Mobile X Ray TB units</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Blood donation units</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>IT equipment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desktops / Laptops / Printers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Incorporators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical incinerators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Non–medical incinerators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Generators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 HZ generators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>60 HZ generators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Material handling equipment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forklifts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Telescopic handlers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Prefabricated buildings</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prefabs for hot regions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prefabs for cold regions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Solar appliances</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solar streetlamps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Solar lanterns</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Solar fridges</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>